secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxart, Inc. (VXRT)
CIK:        0000072444
Form:       8-K
Filed at:   2024-12-27T23:59:59+00:00
Accession:  0001437749-24-038436
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxart secures $37.7M additional BARDA funding for oral COVID-19 vaccine trial
------------------------------------------------------------------------------

- Modification No. 4 increases allotted trial funding from ~$96.5M to ~$134.2M.
- Additional $37.7M for mRNA comparator acquisition and clinical site readiness.
- Total estimated ceiling raised by ~$4.6M to ~$460.7M.
- Trial compares Vaxart's oral XBB COVID-19 vaccine to an FDA-approved mRNA vaccine.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/72444/000143774924038436/0001437749-24-038436-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/72444/000143774924038436/vxrt20241227_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-038436

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer